Increasing Atherosclerosis in Streptozotocin-Induced Diabetes into Four Groups of Mice
Open Access
- 14 February 2018
- journal article
- Published by Scientific Foundation SPIROSKI in Open Access Macedonian Journal of Medical Sciences
- Vol. 6 (2), 287-292
- https://doi.org/10.3889/oamjms.2018.093
Abstract
AIM: To study the protective effect of medicines on the formation of atherosclerosis in mice, it is needed to conduct the study in mice which is not genetically diabetic mice induced by streptozotocin (STZ) to produce hyperglycemia and atherosclerosis, compared with mice treated by yolk or its combination.MATERIAL AND METHODS: Fifty-six mice, Double Deutch Webster strain, male, receive 10 weeks, 20 - 30 gr bodyweight were divided into 4 groups (n = 14) i.e. control (do not received any agents), STZ (45 mg/kg/BW was injected intraperitoneally for 5 days), yolk (0.2 cc orally daily for 6 weeks), and combination of STZ and yolk (STZ: 45 mg/kg/BW intraperitoneally add 0.2 cc yolk orally). All animals were executed in the 42nd day. Then, the aorta of the mice’s heart tissue was histopathology examined. Blood glucose and cholesterol levels were determined every week.RESULTS: Hyperglycemia occurred in mice induced by STZ injection with the highest BGL (521.8 ± 48.2 mg/dl; 188.4%) in the 4th-week observation; after that BGL decrease. We found that, except the control, all treatment groups with STZ, egg yolk, and combination underwent atherosclerosis.CONCLUSION: The present study was able to demonstrate the occurrence of atherosclerosis in mice treated by STZ accompanied with increasing blood glucose and cholesterol level.Keywords
This publication has 19 references indexed in Scilit:
- Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR−/−)Atherosclerosis, 2012
- Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomilVascular Health and Risk Management, 2011
- Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivoAtherosclerosis, 2009
- Diabetic atherosclerosis mouse modelsAtherosclerosis, 2007
- Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient miceAtherosclerosis, 2006
- Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic miceJournal of Drug Targeting, 2005
- Oral Flavonoid Supplementation Attenuates Atherosclerosis Development in Apolipoprotein E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Effect of streptozotocin on the ultrastructure of rat pancreatic isletsMicroscopy Research and Technique, 2004
- Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Increased atherosclerosis in streptozotocin-induced diabetic mice.JCI Insight, 1996